Wilson disease is an
symptoms or a Kayser-Fleischer ring. Six patients with a H714Q mutation in one chromosome and an unknown mutation in the other chromosome presented at a mean age of 17 8 (SD 5 8) years, with either neurological or hepatic symptoms. With the exception of one, all 22 patients with an uncharacterised mutation in both chromosomes presented with liver involvement, at a mean age of 9 9 (SD 2.4) years.
The difference in age at presentation between the H714Q/H714Q group and the patients with an unknown mutation was highly significant (p<00001). This suggests that the H714Q mutation represents a relatively mild mutation, possibly with some residual function in the copper transporting protein, resulting in a slower build up of copper. least 30% of the mutations in the North American Wilson disease population, is a C2142 to A transversion, giving a glutamine instead of histidine residue at amino acid position 714, within the phosphorylation domain of the ATP7B protein.
As genotype can have profound effects on the phenotype, the pivotal example being the relation between the AF508 mutation and pancreatic insufficiency in cystic fibrosis,8 we investigated the relation between age at presentation and the H714Q mutation in Wilson disease patients.
Materials and methods A total of 26 unrelated Dutch families with 38 symptomatic Wilson disease patients were investigated. The diagnosis in each patient was made by a lowered serum caeruloplasmin concentration in combination with either an increased 24 hour urinary copper excretion or a raised liver copper concentration. For each symptomatic patient the age and symptoms at presentation were recorded. The Student t test was used to investigate differences in age at presentation between groups.
High molecular weight DNA was isolated from the peripheral blood leucocytes ofpatients by salt extraction. The probands were specifically tested for the H714Q mutation, which is the result of a C2142 to A transversion in exon 14 (fig 1) . The patients showed either the normal pattern (n = 22), homozygosity for a band shift (n = 10), or heterozygosity for the two patterns (n = 6) (table) . Direct sequence analysis of several patients showed that the shifted band is caused by the C2142 to A transversion (fig 2) . No other abnormalities were identified in the amplified fragment. A panel of 40 normal people was similarly screened. All subjects showed the normal pattern. The 10 patients homozygous for the H714Q mutation presented at a mean age of 20-3 (SD 6-1) years (range 16-37 years) (table). However, patients with an at present unknown mutation in both chromosomes presented at a mean age of 9 9 (SD 2A4) years (range 6-15 years) (p<0-0001). Patients with a H714Q mutation in one chromosome and a so far unknown mutation in the other, turned out to have an intermediate age at presentation: 17-8 (SD 5-8) years (range 10-24 years), significantly different (p<0-0001) from patients with an unknown mutation in both chromosomes but not from patients homozygous for the H714Q mutation.
Nine out of the 10 patients homozygous for the H714Q mutation presented with neurological or psychiatric symptoms, although in some patients concomitant liver cirrhosis was found at diagnosis. In one patient homozygous for the H714Q mutation a Kayser-Fleischer ring was accidently discovered when he went to the ophthalmologist for a new pair of glasses. The probable diagnosis ofWilson disease in this patient was subsequently proven by standard biochemical methods. This extrahepatic mode of presentation was very different from the 22 patients with an at present uncharacterised mutation in both chromosomes. Twenty of these patients presented with severe liver disease and half of those progressed to overt liver failure. One patient presented with abdominal pain. During subsequent investigations raised transaminases were discovered, which led to the diagnosis of Wilson disease in this patient. One other patient presented with neurological symptoms. At 15 years of age this patient was the oldest in this group. Three out of six We now find that the H714Q mutation is indeed associated with late, neurological presentation in Wilson disease. Given the very significant difference in age at presentation between patients with and without an H714Q mutation, we hypothesise that this mutation probably leaves the ATP7B protein with some residual copper excretory capacity. Although the histidine residue in the phosphorylation domain of ion transport ATPases is strongly conserved between species,6 and consequently should be important for the function of the protein, this mutation does not result in a premature stop codon or frameshift, so preservation of some excretory function does not seem unlikely. However, some rare mutations have been described that result in a premature stop codon or a frameshift.46 Although no correlation with phenotype has been given yet, patients with this type of mutation might present at a young age with liver involvement, owing to a totally non-functional ATP7B protein.
It is unclear why the H714Q mutation has become that prevalent in the United States, the Russian,5 as well as the Dutch Wilson disease population. The existence of a carrier advantage, protecting against a state of copper deficiency seems unlikely, because this is a very rare event in people not on parenteral nutrition.' Probably chance effects are responsible for the high prevalence of the H7 14Q mutation within the Wilson disease population.
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